BUFFALO, N.Y. -- The University at Buffalo Biosciences Incubator
has selected its first tenants: AccuTheranostics, AndroBioSys and
Ceno Technologies, three companies that will benefit from the
facility's location at UB's Clinical and Translational Research
Center on the Buffalo Niagara Medical Campus (BNMC).
AccuTheranostics, previously based in the UB Technology
Incubator at Baird Research Park in Amherst, is dedicated to
helping cancer patients personalize chemotherapy treatment to
achieve the best possible results.
AndroBioSys, the brainchild of two Roswell Park Cancer Institute
researchers, is developing novel ways to detect, image and treat
early prostate cancer.
And Ceno Technologies, a materials science company, is moving
its biological sciences division to the incubator, where Ceno
researchers will study and develop nanoparticles for delivering
Executives at all three firms cite the UB Biosciences
Incubator's proximity to potential research and clinical partners
as a key benefit.
"We are on the medical campus now, which means we will have
better and easier communication with the Roswell staff," said
Sherry Bradford, founding president of AccuTheranostics, which
relocated to the incubator this August.
The 4,000-square-foot incubator houses offices and
state-of-the-art wet labs on the fifth floor of the Clinical and Translational
Research Center (CTRC)/Gates Vascular Institute. The 10-story
building, which UB and Kaleida Health and UB jointly opened earlier
this year, is at the corner of Goodrich and Ellicott Street in
The incubator is run by UB's Office of Science, Technology
Transfer and Economic Outreach (STOR). Clients pay to rent space,
but receive free access to services such as specialized equipment;
seminars on entrepreneurship; guidance on business needs such as
marketing; and assistance applying for grants and seeking
These resources are particularly helpful for life science
entrepreneurs -- like Bradford -- who come from research
backgrounds and have limited experience in the business world.
"STOR facilitates the transfer of UB discoveries into
enterprises that create value and provide products and services
that benefit the public good," said UB Associate Vice Provost Woody
Maggard, who oversees STOR's incubator program. "One of the key
ways we do this is through incubating new companies, just as we
have at the Baird Research Park since 1988. The UB Biosciences
Incubator will extend this effort by collaborating with the CTRC to
bring additional UB discoveries to market."
AccuTheranostics is dedicated to helping doctors identify which
chemotherapy treatments will likely work on a patient's tumor --
and which likely won't.
To achieve this goal, the company tests different chemotherapy
combinations on cells biopsied from patients' tumors. These tests
reveal which mixtures of drugs are likely to be effective in
combatting each individual's unique cancer, said Sherry Bradford,
PhD, the firm's founding president.
So far, AccuTheranostics has screened hundreds of tumors. The
firm's ChemoFit test has been 98 percent accurate in identifying
resistant drugs and 97 percent accurate in identifying effective
drugs, Bradford said.
As an oncology researcher, Bradford finds entrepreneurship
rewarding because of the difference she is making in people's
lives. She recalls what one cancer patient told her about
chemotherapy, which can cause debilitating side effects: "It's one
thing to get sick on a drug that works. It's another thing to get
sick on a drug that doesn't work," the patient said, according to
"That's why we do what we do," Bradford said.
As incubator clients, Bradford and her colleagues have attended
seminars on topics including marketing and intellectual property.
UB's Office of Science, Technology Transfer and Economic Outreach
introduced the firm to its attorneys and a business consultant.
Bradford said moving into the UB Biosciences Incubator will help
AccuTheranostics grow. The firm is applying for certification under
New York State's Clinical Laboratory Evaluation Program, which is
necessary for the company to receive health insurance
reimbursements for its services, company representatives said.
AndroBioSys specializes in advanced detection, diagnostic
imaging and therapeutics for early prostate cancer. One of the
company's major goals is to develop techniques that will enable
doctors to target drugs and imaging agents specifically to the
prostate, while limiting the exposure of these chemicals in other
parts of the body.
The company's founders are Gary J. Smith and James L. Mohler,
both researchers at Roswell Park Cancer Institute. Smith, PhD, is a
member of Roswell's prostate program and a member of the
institute's urology department. Mohler, MD, another prostate cancer
expert, chairs Roswell's urology department and serves as Roswell's
senior vice president for translational research. Mohler is also a
professor of urology at UB.
Smith said AndroBioSys is working to address one of the most
important issues in prostate cancer treatment today: the need to
give doctors better tools for predicting which prostate tumors will
threaten patients' lives.
"Statistically, one in six men is diagnosed with prostate
cancer. However, the vast majority of these cancers remain
clinically insignificant, such that the person is likely to die
with the cancer, and not of the cancer," Smith said. "Since the two
groups can't be differentiated, the tendency is to treat all people
aggressively, and the downside to that is two-fold. It's very
expensive, and second, there is a high probability of side effects
like incontinence and impotence to what may be unnecessary
treatment, which really changes the quality of life."
AndroBioSys is developing a serum-based diagnostic assay for
detecting prostate cancer and identifying the subset of patients in
which the cancer is likely to progress in a dangerous manner.
The company is also studying techniques for targeting imaging
agents and treatments like chemotherapy to the prostate blood
vessels. Smith said the firm's new location in the UB Biosciences
Incubator will be beneficial to this research, helping to
facilitate partnerships with UB researchers focused on developing
innovative technologies in microvascular imaging.
About Ceno Technologies
Ceno Technologies is a global leader in developing high-quality
advanced particle technologies. The firm's scientists develop novel
materials for use by the automotive, manufacturing, military,
pharmaceutical and other industries.
While Ceno Technologies formed in 2007 with a focus on materials
science, the company quickly branched out into biomedical research,
investigating the use of small particles to deliver drugs and
support photodynamic therapy for an array of diseases.
The firm is based at the Innovation Center on the Buffalo
Niagara Medical Campus, but will move its Bio Division to the UB
This relocation will facilitate partnerships with medical
researchers. It will also enable the company to isolate biological
sciences experiments from other materials work, reducing the risk
of cross-contamination, said Scottpatrick Sellitto, CEO of Ceno
Both these factors are important as the company looks to expand
its work in the biomedical sector, with the hope of bringing new
research and manufacturing jobs to Western New York, he said.
"We do plan on expanding as much as we can," Sellitto said.
"We're growing quite well, and I believe it's a very promising
year. The move to the Clinical and Translational Research Center
building is going to be very helpful not just for us, but also for
the partners we want to help. We collaborate with a lot of medical
doctors, PhDs and university professors who have requested our